Abstract
Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1495-1509 |
| Number of pages | 15 |
| Journal | Current Drug Targets |
| Volume | 13 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 3 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Breast cancer
- Molecular technology
- Proteome
- RPPA
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Clinical Biochemistry
Cite this
Proteomic classification of breast cancer. / Kamel, Dalia; Brady, Bernadette; Tabchy, Adel; Mills, Gordon; Hennessy, Bryan.
In: Current Drug Targets, Vol. 13, No. 12, 03.12.2012, p. 1495-1509.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Proteomic classification of breast cancer
AU - Kamel, Dalia
AU - Brady, Bernadette
AU - Tabchy, Adel
AU - Mills, Gordon
AU - Hennessy, Bryan
PY - 2012/12/3
Y1 - 2012/12/3
N2 - Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
AB - Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
KW - Breast cancer
KW - Molecular technology
KW - Proteome
KW - RPPA
UR - http://www.scopus.com/inward/record.url?scp=84870183727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870183727&partnerID=8YFLogxK
U2 - 10.2174/138945012803530080
DO - 10.2174/138945012803530080
M3 - Article
C2 - 22974393
AN - SCOPUS:84870183727
VL - 13
SP - 1495
EP - 1509
JO - Current Drug Targets
JF - Current Drug Targets
SN - 1389-4501
IS - 12
ER -